Pay-For-Delay Has A Tough (Antitrust) Time At EU Top Court
By EsqSocial Corporation 20/04/21
In recent years, there have been various antitrust investigations in the pharmaceutical sector resulting in decisions of the European Commission (EC) and the European Courts. In two recent rulings – “Lundbeck and “Paroxetine” – the European Court of Justice (ECJ) dealt with settlement agreements between originator companies and generic companies aimed at delaying the introduction of generic drugs to the market, so-called “pay-for-delay” or “reverse patent settlement” agreements......
By: MoFo Life Sciences